Last reviewed · How we verify

NCT05237817: ABSAI

Association Between Stroke and Adrenal Incidentalomas

Recruiting now Last updated 14 February 2022
What this trial tests

trial in Stroke in 2 participants. Currently enrolling.

Timeline
1 April 2021
Primary endpoint
1 April 2022
28 February 2029

Quick facts

Lead sponsorXuanwu Hospital, Beijing
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2
Start date1 April 2021
Primary completion1 April 2022
Estimated completion28 February 2029
Sites1 location across China

Conditions studied

Sponsor

Xuanwu Hospital, Beijing

Who can join

Adults 18 to 100, any sex, with Stroke or Adrenal Incidentaloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke. Stroke is a diseases which could cause of disability and death worldwide. In clinical practice, detailed information about the association between stroke and AIs is not available. In this study, the investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05237817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing